

Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Tafluprost Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD 120 Moorgate EC2M 6UR London, United Kingdom
	Telephone	:	+44 (0) 2081548000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

EUH210 Safety data sheet available on request.



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Tafluprost	209860-87-7	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 1B; H360D STOT SE 1; H370 (Lungs, Cardio- vascular system) STOT RE 1; H372 (Lungs, Cardio- vascular system) Aquatic Chronic 4; H413	>= 0.0002 - < 0.0025
Substances with a workplace exposure	e limit :		
Glycerine	56-81-5 200-289-5		>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders	:	No special precautions are necessary for first aid responders.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.



Tafluprost Formulation

Version 5.1	Revision Date: 28.09.2024		9S Number: 72636-00008	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
	: important symptoms a e known.	nd e	ffects, both acute	and delayed
	ation of any immediate a atment	meo :		I special treatment needed cally and supportively.
SECTIO	N 5: Firefighting meas	sur	es	
5.1 Extir	iguishing media			
Suit	able extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
Uns mec	uitable extinguishing lia	:	None known.	
5.2 Spec	ial hazards arising from	the	substance or mi	xture
Spe fight	cific hazards during fire- ting	:	Exposure to com	oustion products may be a hazard to health.
Haz ucts	ardous combustion prod-	:	Carbon oxides	
5.3 Advi	ce for firefighters			
	cial protective equipment irefighters	:		ed breathing apparatus for firefighting if nec- onal protective equipment.
Spe ods	cific extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

-		
Personal precautions	Follow safe h	handling advice (see section 7) and personal pro-
	tective equip	oment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment.
	Prevent further leakage or spillage if safe to do so.
	Prevent spreading over a wide area (e.g. by containment or oil
	barriers).
	Retain and dispose of contaminated wash water.
	If spillage enters rivers or watercourses, inform the Environ-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 9372636-00008	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		ment Agency (e	emergency telephone number 0800 807060).
6.3 Metho	ds and material for c	ontainment and clea	ning up
Metho	ods for cleaning up	For large spills, ment to keep m be pumped, sto Clean up remai bent. Local or nationa posal of this ma employed in the mine which reg Sections 13 and	ert absorbent material. provide dyking or other appropriate contain- laterial from spreading. If dyked material can bre recovered material in appropriate container. ning materials from spill with suitable absor- al regulations may apply to releases and dis- laterial, as well as those materials and items e cleanup of releases. You will need to deter- ulations are applicable. d 15 of this SDS provide information regarding national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

The reconductions for sale handling	,	
Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
7.2 Conditions for safe storage, i	nc	luding any incompatibilities
Requirements for storage areas and containers	:	Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents Gases
7.3 Specific end use(s)		
Specific use(s)	:	No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Glycerine	56-81-5	TWA (Mist)	10 mg/m3	GB EH40
Tafluprost	209860-87-	TWA	0.002 µg/m3 (OEB 5)	Internal
	7			
	Further inform	ation: Skin, Eye		
		Wipe limit	0.02 μg/100 cm ²	Internal

Derived No Effect Level (DNEL)

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Glycerine	Workers	Inhalation	Long-term local ef- fects	56 mg/m3
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local ef- fects	33 mg/m3

Predicted No Effect Concentration (PNEC)

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0.885 mg/l
	Marine water	0.0885 mg/l
	Intermittent use/release	8.85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3.3 mg/kg dry weight (d.w.)
	Marine sediment	0.33 mg/kg dry weight (d.w.)
	Soil	0.141 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection

: Wear safety glasses with side shields or goggles.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 9372636-00008	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Hand	protection	mists or aero Wear a faces	avironment or activity involves dusty conditions, sols, wear the appropriate goggles. hield or other full face protection if there is a direct contact to the face with dusts, mists, or
		Chamical roa	intent aloues
IVIč	aterial	: Chemical-res	stant gloves
	emarks and body protection	Additional boo being perform suits) to avoid	or laboratory coat. dy garments should be used based upon the task ned (e.g., sleevelets, apron, gauntlets, disposable l exposed skin surfaces. ate degowning techniques to remove potentially
	ratory protection ter type	: If adequate lo sure assessm ommended g	cal exhaust ventilation is not available or expo- lent demonstrates exposures outside the rec- uidelines, use respiratory protection. lould conform to BS EN 14387

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

mormation on pasic physical	an	a chemical properti
Appearance Colour	:	Aqueous solution clear
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version 5.1	Revision Date: 28.09.2024		last issue: 06.04.2024 first issue: 27.08.2021
Relati	ve density	: No data available	
Densi	ty	: No data available	
Wa Partiti octan Auto-i	ility(ies) ater solubility on coefficient: n- ol/water gnition temperature mposition temperature	 No data available No data available No data available No data available 	
	scosity, kinematic	: No data available	
Explo	sive properties	: Not explosive	
Oxidiz	zing properties	: The substance or mixture	is not classified as oxidizing.
Flamr	information nability (liquids) cular weight le size	No data availableNo data availableNo data available	

SECTION 10: Stability and reactivity

10.1	Reactivity		4
10.2	Not classified as a reactivity has Chemical stability Stable under normal conditions		J.
10.3	Possibility of hazardous reac Hazardous reactions		ns Can react with strong oxidizing agents.
10.4	Conditions to avoid Conditions to avoid	:	None known.
10.5	Incompatible materials Materials to avoid	:	Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

SECTION 11: Toxicological information

11.1 Information on toxicological effects Information on likely routes of : Inhalation exposure Skin contact Ingestion Eye contact Acute toxicity Not classified based on available information. **Components:** Tafluprost: Acute oral toxicity LD50 (Rat): 665 mg/kg : LD50 (Rat): > 100 mg/kg Remarks: No mortality observed at this dose. Acute toxicity (other routes of : (Dog): 3 mg/kg administration) **Application Route: Intravenous** Target Organs: Cardio-vascular system **Glycerine:** LD50 (Rat): > 5,000 mg/kg Acute oral toxicity : Acute dermal toxicity LD50 (Guinea pig): > 5,000 mg/kg :

Skin corrosion/irritation

Not classified based on available information.

Components:

Glycerine:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Tafluprost:

Species	:	Monkey
Result	:	No eye irritation

Glycerine:

Species	:	Rabbit
Result	:	No eye irritation

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Tafluprost:	
Toot Tupo	

•	
Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Tafluprost:	
Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative
Genotoxicity in vivo :	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative
Glycerine:	
Genotoxicity in vitro :	Test Type: In vitro mammalian cell gene mutation test Result: negative
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative
	Test Type: DNA damage and repair, unscheduled DNA syn- thesis in mammalian cells (in vitro) Result: negative

Carcinogenicity

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 9372636-00008	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Com	oonents:		
Speci Applic	cation Route sure time	: Rat : Subcutaneous : 24 Months : negative	
	cation Route sure time	: Mouse : Subcutaneous : 18 Months : negative	
	es cation Route sure time	: Rat : Ingestion : 2 Years : negative	
Not cl	oductive toxicity lassified based on ava ponents:	ilable information.	
	prost: is on fertility	Species: Rat	
Effect ment	s on foetal develop-	Species: Rat Application Rou Developmental	oryo-foetal development ute: Intravenous injection Toxicity: LOAEL: 10 μg/kg nations were observed., Reduced foetal weigh
		Species: Rat Application Rou	oryo-foetal development ute: Intravenous injection Toxicity: NOAEL: 3 μg/kg
		Species: Rabbi Application Rou Developmental	oryo-foetal development t ute: Intravenous injection Toxicity: LOAEL: 0.03 μg/kg nations were observed.
		Species: Rabbi Application Rou	oryo-foetal development t ute: Intravenous injection Toxicity: NOAEL: 0.01 μg/kg

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

ersion I	Revision Date: 28.09.2024		OS Number: 72636-00008	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
			Species: Rat Application Rou	pryo-foetal development ite: Intravenous injection Toxicity: LOAEL: 1 μg/kg
			Species: Rat Application Rou	oryo-foetal development ite: Intravenous injection Toxicity: NOAEL: 0.3 μg/kg
Repro sessn	oductive toxicity - As- nent	:	Clear evidence animal experim	of adverse effects on development, based or ents.
Glyce	erine:			
-	s on fertility	:	Test Type: Two Species: Rat Application Rou Result: negative	
Effects on foetal develop- ment		:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative	
Not cl	- single exposure assified based on avai conents:	lable	information.	
	prost:			
Targe	t Organs ssment	:	Lungs, Cardio- Causes damag	
	- repeated exposure			
Not cl			information	
C	assified based on avai	lable		
Taflu Targe	assified based on avai ponents: prost: t Organs ssment		Lungs, Cardio-v	vascular system e to organs through prolonged or repeated
Taflu Targe Asses	ponents: prost: t Organs		Lungs, Cardio-\ Causes damag	
Taflu Targe Asses Repe	ponents: prost: t Organs ssment		Lungs, Cardio-\ Causes damag	
Taflu Targe Asses Repe	oonents: prost: It Organs ssment ated dose toxicity		Lungs, Cardio-\ Causes damag	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Species:DogNOAEL:0.0001LOAEL:0.001Application Route:Intrave:Exposure time:39 WeTarget Organs:CardioSymptoms:DilatatGlycerine:Species:RatNOAEL:0.622Application Route:inhalatExposure time:13 WeSpecies:RatNOAEL:NOAEL:Application Route:IngestExposure time:2 yrSpecies:RatNOAEL:Species:RatNOAEL:Species:RatNOAEL:Species:RabitNOAEL:Species:RabitNOAEL:Species:RabitNOAEL:Species:RabitNOAEL:Species:RabitNOAEL:Species:RabitNOAEL:Species:RabitNOAEL:Species:Species:RabitNOAEL:Species:Species: <th>ths -vascular system, Blood, Bone marrow, Kidney, Liver, mg/kg mg/kg enous</th>	ths -vascular system, Blood, Bone marrow, Kidney, Liver, mg/kg mg/kg enous
NOAEL:0.0001LOAEL:0.001Application Route:IntraveExposure time:39 WeTarget Organs:CardicSymptoms:DilatatGlycerine:Species:RatNOAEL:0.167LOAEL:0.622Application Route:inhalatExposure time:13 WeSpecies:RatNOAEL:8,000Application Route:IngestExposure time:2 yrSpecies:RabbitNOAEL:5,040Application Route:Skin cExposure time:45 WeAspiration toxicityNot classified based on available information	mg/kg enous eks -vascular system, Eye
Species:RatNOAEL:0.167LOAEL:0.622Application Route:inhalatExposure time:13 WeSpecies:RatNOAEL:8,000Application Route:IngestExposure time:2 yrSpecies:RabbitNOAEL:5,040Application Route:Skin cExposure time:45 WeAspiration toxicityNot classified based on available information	
NOAEL:0.167LOAEL:0.622Application Route:inhalatExposure time:13 WeSpecies:RatNOAEL:8,000Application Route:IngestExposure time:2 yrSpecies:RabbitNOAEL:5,040Application Route:Skin cExposure time:45 WeAspiration toxicityNot classified based on available information	
NOAEL:8,000Application Route:IngestExposure time:2 yrSpecies:RabbitNOAEL:5,040Application Route:Skin cExposure time:45 WeAspiration toxicityNot classified based on available information	mg/l ion (dust/mist/fume)
NOAEL: 5,040Application Route: Skin cExposure time: 45 WeAspiration toxicityNot classified based on available information	- 10,000 mg/kg on
Not classified based on available informa	mg/kg ontact
	tion.
Experience with human exposure	
Components:	
Tafluprost:Eye contact: Sympt	oms: dryness of the eyes, Blurred vision
SECTION 12: Ecological information	
12.1 Toxicity	
-	
Components:	
	Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l ure time: 96 h
	(Daphnia magna (Water flea)): 1,955 mg/l ure time: 48 h

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version 5.1	Revision Date: 28.09.2024		DS Number: 72636-00008	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Τοχία	sity to microorganisms	:	NOEC (Pseudor Exposure time: 1 Method: DIN 38	
12.2 Pers	istence and degradabi	ility		
Com	ponents:			
Glyc	erine:			
Biode	egradability	:	Result: Readily b Biodegradation: Exposure time: 3 Method: OECD	92 %
12.3 Bioa	ccumulative potential			
Com	ponents:			
Parti	iprost: tion coefficient: n- nol/water	:	log Pow: 4.5	
Parti	erine: tion coefficient: n- nol/water	:	log Pow: -1.75	
	ility in soil ata available			
12.5 Res	ults of PBT and vPvB a	isse	ssment	
Prod	uct:			
Asse	ssment	:	to be either pers	nixture contains no components considered istent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Othe	er adverse effects			
Prod	uct:			
	ocrine disrupting poten-	:	ered to have end	nixture does not contain components consid- locrine disrupting properties for environment REACH Article 57(f).

13.1 Waste treatment methods

Product

: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.



Tafluprost Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.20249372636-00008Date of first issue: 27.08.2021	
Conta	aminated packaging	 Waste codes should be assigned by the user, preferab discussion with the waste disposal authorities. Do not dispose of waste into sewer. Empty containers should be taken to an approved was dling site for recycling or disposal. If not otherwise specified: Dispose of as unused production. 	te han-
SECTION	N 14: Transport info	nation	
14.1 UN n	umber		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDO	3	: Not regulated as a dangerous good	
ΙΑΤΑ		: Not regulated as a dangerous good	
14.2 UN p	roper shipping name		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDO	3	: Not regulated as a dangerous good	
ΙΑΤΑ		: Not regulated as a dangerous good	
14.3 Tran	sport hazard class(es		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDO	3	: Not regulated as a dangerous good	
ΙΑΤΑ		: Not regulated as a dangerous good	
14.4 Pack	ing group		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDO	3	: Not regulated as a dangerous good	
ΙΑΤΑ	(Cargo)	: Not regulated as a dangerous good	
ΙΑΤΑ	(Passenger)	: Not regulated as a dangerous good	
14.5 Envi	ronmental hazards		
Not r	egulated as a dangerou	good	
-	ial precautions for us		
Not a	pplicable		

Not applicable



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	:	Not applicable
UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	:	Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain)	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	:	Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	:	Not applicable
Control of Major Accident Hazards Regulations 2015 (CC Not applicable	OMA	\H)

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 :	Harmful if swallowed.
H319 :	Causes serious eye irritation.
H360D :	May damage the unborn child.
H370 :	Causes damage to organs if swallowed.
H372 :	Causes damage to organs through prolonged or repeated exposure if swallowed.
H413 :	May cause long lasting harmful effects to aquatic life.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

Full text of other abbreviations

Acute Tox. Aquatic Chronic Eye Irrit.	::	Acute toxicity Long-term (chronic) aquatic hazard Eye irritation
Repr. STOT RE STOT SE		Reproductive toxicity Specific target organ toxicity - repeated exposure Specific target organ toxicity - single exposure
GB EH40 GB EH40 / TWA		UK. EH40 WEL - Workplace Exposure Limits Long-term exposure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response: GHS - Globally Harmonized System: GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations: UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	28.09.2024	9372636-00008	Date of first issue: 27.08.2021

considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN